




		EMLc	ATC codes: J01CA04
Indication	Acute pharyngitis	ICD11 code: CA02	
INN	Amoxicillin		
Medicine type	Chemical agent		
Antibiotic groups	<div>A ACCESS</div>		
List type	Core (EML) (EMLc)		
Formulations	Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid (EMLc) ; 250 mg per 5 mL (as trihydrate) powder for oral liquid (EMLc) Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection ; 500 mg in vial (as sodium) powder for injection ; 1 g in vial (as sodium) powder for injection Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate) (EMLc) ; 500 mg (scored) (as trihydrate) (EMLc) Oral > Solid > dosage form: 250 mg (as trihydrate) ; 500 mg (as trihydrate)		
EML status history	First added in 2017 (TRS 1006) Changed in 2023 (TRS 1049)		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more about patents . 		
Wikipedia	Amoxicillin 		
DrugBank	Amoxicillin 		

Expert Committee recommendation

In consideration of the review of the age appropriateness of formulations of medicines on the EMLc, and the comparison report of the EML versus EMLc, the Expert Committee recommended changes to the EMLc for addition of new, age-appropriate formulations and strengths of existing essential medicines, deletion of unavailable or age-inappropriate formulations and strengths, and other listing modifications as proposed in the application. The Committee also endorsed the proposals for further review of the public health relevance and evidence for specific medicines for use in children for potential future consideration for inclusion on the EMLc. The Committee noted and welcomed the ongoing review being coordinated by the Secretariat for the remaining sections of the EMLc for consideration by the 2025 Expert Committee. As a result of the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of new formulations of amoxicillin (dispersible, scored tablet, 250 mg and 500 mg) to the EMLc. - the addition of new formulations of cefalexin (dispersible tablet 125 mg and 250 mg) to the EMLc. - the addition of a new strength formulation of clarithromycin (solid oral dosage form 250 mg) to the EMLc. - the deletion of clarithromycin 500 mg solid oral dosage form from the EMLc.

EML recommendations: Acute pharyngitis

First choice

Second choice

WATCHFUL WAITING, SYMPTOM RELIEF AND NO ANTIBIOTIC TREATMENT SHOULD BE CONSIDERED AS THE FIRST-LINE TREATMENT OPTION.

phenoxymethylpenicillin

clarithromycin

amoxicillin

cefalexin

